Skip to main content

Ann Richmond Archives

Study identifies key regulator of melanoma development

Jun. 29, 2023—Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity.

Read more


Melanoma treatment response

Feb. 24, 2022—Targeting the interaction between melanoma and immune cells could improve responses to targeted cancer therapies, Vanderbilt researchers found.

Read more


Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma

Jul. 1, 2021—A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.

Read more


Study reveals new strategy for reducing tumor growth, metastasis

Dec. 17, 2020—A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma.

Read more


Richmond steps down as associate director for Research Education for VICC

Jul. 16, 2020—After serving 16 years as associate director for Research Education at Vanderbilt-Ingram Cancer Center (VICC), Ann Richmond, PhD, Ingram Professor of Cancer Research, is stepping down from the leadership post.

Read more


Study explores melanoma drug’s effectiveness

Apr. 23, 2020—A study by Vanderbilt research-ers supports the clinical development of a new second-line treatment for metastatic melanoma.

Read more


Richmond receives legacy award from Society for Leukocyte Biology

Dec. 12, 2019—Ann Richmond, PhD, Ingram Professor of Cancer Research, is the 2019 recipient of the Society for Leukocyte Biology Legacy Award.

Read more


Potential second-line melanoma treatment identified

Aug. 15, 2019—A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients.

Read more


15 faculty members elected as AAAS fellows

Nov. 20, 2017—Fifteen Vanderbilt faculty members conducting a range of biomedical and clinical research have been elected fellows of the American Association for the Advancement of Science. Six of the 15 have received funding through the university’s Trans-Institutional Programs initiative, which facilitates research and teaching collaborations across disciplines and are a core pillar of the university’s Academic Strategic Plan.

Read more


Veterans Affairs Research Conference

Jun. 1, 2017—The 3rd National Veterans Health Affairs Research Conference held at Vanderbilt University Medical Center May 17-18.

Read more


Richmond to speak at national VA research conference on cancer immunotherapy

May. 11, 2017—Vanderbilt University cancer researcher Ann Richmond, Ph.D., 2016 recipient of one of the highest honors for scientific achievement bestowed by the U.S. Department of Veterans Affairs, will be a keynote speaker during a national VA research conference next week at Vanderbilt University School of Medicine.

Read more


Top cancer researchers reveal latest findings at VICC science retreat

May. 11, 2017—Ordinary cells can be transformed into cancer cells through epigenetics — changes to DNA that turn genes on or off. Those gene changes can protect cells or make them vulnerable to disease processes including cancer.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more